Paradoxically, despite worse outcomes for patients with HR+PIK3CA-mutant breast cancer, patients with PIK3CA-mutant TNBC tend to have higher rates of overall survival compared with patients with subtype-matched tumors that express wild-type PIK3CA (24). This evidence concerns the gene PIK3CA and breast carcinoma.